AVITA Medical Reports Third Quarter 2022 Financial Results
10. November 2022 16:01 ET
|
AVITA Medical
VALENCIA, Calif. and MELBOURNE, Australia, Nov. 10, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a regenerative medicine company leading the development and...
AVITA Medical Announces Achievement of Co-Primary Endpoints in Updated Analysis of Pivotal Trial of RECELL® System for Soft Tissue Repair
09. November 2022 18:45 ET
|
AVITA Medical
VALENCIA, Calif. and MELBOURNE, Australia, Nov. 09, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and...
AVITA Medical Announces FDA Breakthrough Device Designations for the RECELL® System
03. November 2022 20:15 ET
|
AVITA Medical
VALENCIA, Calif. and MELBOURNE, Australia, Nov. 03, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and...
AVITA Medical to Announce Third Quarter 2022 Financial Results
20. Oktober 2022 16:01 ET
|
AVITA Medical
VALENCIA, Calif. and MELBOURNE, Australia, Oct. 20, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and...
AVITA Medical Appoints Industry Leader James Corbett as Chief Executive Officer
28. September 2022 19:06 ET
|
AVITA Medical
VALENCIA, Calif. and MELBOURNE, Australia, Sept. 28, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and...
Investor Webinar Briefing
13. September 2022 16:11 ET
|
AVITA Medical
VALENCIA, Calif. and MELBOURNE, Australia, Sept. 13, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and...
AVITA Medical Achieves Positive Topline Pivotal Trial Results for Treatment of Stable Vitiligo Using the RECELL® System
12. September 2022 16:23 ET
|
AVITA Medical
The study achieved its primary effectiveness endpoint of super-superiority AVITA Medical continues to plan for submission to FDA by the end of 2022 VALENCIA, Calif. and MELBOURNE, Australia, Sept. ...
RECELL System Insurance Coverage Begins in Japan for Treatment of Acute Burns
01. September 2022 08:00 ET
|
AVITA Medical
VALENCIA, Calif. and MELBOURNE, Australia, Sept. 01, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and...
RECELL® System Data to be Presented at the Controversies and Conversations in Laser & Cosmetic Surgery Annual Meeting
17. August 2022 16:50 ET
|
AVITA Medical
VALENCIA, Calif. and MELBOURNE, Australia, Aug. 17, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a...
AVITA Medical Reports Second Quarter 2022 Financial Results
11. August 2022 16:06 ET
|
AVITA Medical
VALENCIA, Calif. and MELBOURNE, Australia, Aug. 11, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a regenerative medicine company that is developing and...